. The relatively short half-life (3 to 5 h) and the lack of polyglutamation of PTX makes a continuous administration of this agent attractive. Consequently, phase I and II studies of PTX were conducted using prolonged, low-dose oral schedules (Feun et al., 1991a,b). Myelosuppression proved to be dose-limiting. Antitumour activity was observed in patients with malignant melanoma and urothelial cancer (Weiss et al., 1989; Feun et al., 1991a,b 
Piritrexim (2,4 -diamino -6[2,5 -dimethoxybenzyl] -5 -methyl pyrido - [2,3d] pyrimidine; PTX) is a new, lipid-soluble dihydrofolate reductase (DHFR) inhibitor (Duch et al., 1982; Sedwick et al., 1982; Sigel et al., 1987) . The drug differs from methotrexate (MTX) in that it crosses membranes rapidly by passive diffision and cannot be polyglutamated, therefore the intracellular levels are expected to parallel plasma levels in highly perfused tissues. PTX is as potent as MTX in vitro as an inhibitor of DHFR. Bioavailability after oral dosing is approximately 75% (Weiss et al., 1989) . The relatively short half-life (3 to 5 h) and the lack of polyglutamation of PTX makes a continuous administration of this agent attractive. Consequently, phase I and II studies of PTX were conducted using prolonged, low-dose oral schedules (Feun et al., 1991a,b) . Myelosuppression proved to be dose-limiting. Antitumour activity was observed in patients with malignant melanoma and urothelial cancer (Weiss et al., 1989; Feun et al., 1991a,b) . The recommended dose for further phase II studies was 25 mg three times a day for 5 days (Feun et al., 1991b 
Toxicity
The most frequent toxicities are listed in Table II . The major toxicities were leukopenia and thrombocytopenia, which however were manageable and rapidly reversible; recovery from nadir was usually reached within a few days after treatment interruption and never required more than 7 days. There were no episodes of bleeding or leucopenic fever. In six patients grade 3-4 myelotoxicity developed quite suddenly (De Wit et al., 1992) . In three patients we noted the development of low grade hemolytic anaemia during the course of treatment that was rapidly reversible upon cessation of PTX. An example is shown in Figure 1 . To our knowledge this side effect has not been reported previously. Dose escalation was performed only in three patients. In view of the myelotoxicity observed in the first five patients, no further dose escalations were performed. A one step dose reduction was performed in 13 patients, and a second step was made in seven patients.
Discussion
Presently, DDP and MTX are the most commonly used single agents in the treatment of advanced transitional cell cancer of the urothelial tract, with average response rates of 24% in 629 patients and 29% in 236 patients, respectively. The responses were usually partial and of short duration (median 3 to 6 months) (Yagoda, 1987; Oliver et al., 1986; Khandekar et al., 1985; Troner et al., 1987; Hillcoat et al., 1989; Loehrer et al., 1990) . In an attempt to improve the results various combinations of DDP and MTX with or without other agents have been studied. Although with combination chemotherapy response rates have increased to 40-70%, the median duration of response and survival is still less than 1 year, whereas such intensive combination chemotherapy is at the cost of considerable toxicity (Oliver et al., 1986; Khandekar et al., 1985; Troner et al., 1987; Hillcoat et al., 1989; Loehrer et al., 1990; Stoter et al., 1987; Harker et al., 1985; Yagoda, 1989; Stemnberg et al., 1989; Logothetis et al., 1990a, b myelosuppression. Other toxicities included skin rash that required early cessation of PTX treatment in two cases, and mild nausea and vomiting. Three patients developed hemolytic anaemia during treatment, and one patient developed reversible interstitial pulmonary changes, that were attributed to PTX. In several patients we observed the sudden development of myelotoxicity, after prolonged treatment periods without significant previous myelotoxicity, whereas other patients demonstrated spontaneous recovery from grade 1 toxicity despite treatment continuation. This may be indicative of intra-patient variability of drug resorption, and because of its unpredictable nature necessitated weekly determinations of blood counts (Weiss et al., 1989) . Without exceptions all side-effects were rapidly reversible after discontinuation of drug administration.
In conclusion, PTX appears to be an active agent in patients with advanced urothelial cancer when administered as a 5-day, low-dose oral schedule. Furthermore, the drug is well tolerated with myelosuppression as the major toxicity, that is sometimes unpredictable and frequently requires dose modification. It would be attractive to investigate the combination of PTX and cisplatin.
